Veritas Pharma Inc
Indigenous Bloom Hemp Corp. focuses on the production of hemp products. It sells hemp biomass and flowers, as well as phytocannabinoid rich extracts derived from hemp biomass. The company is headquartered in Kelowna, Canada.
Veritas Pharma Inc (VRTHF) - Total Assets
Latest total assets as of February 2023: $560.94K USD
Based on the latest financial reports, Veritas Pharma Inc (VRTHF) holds total assets worth $560.94K USD as of February 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Veritas Pharma Inc - Total Assets Trend (2014–2022)
This chart illustrates how Veritas Pharma Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Veritas Pharma Inc - Asset Composition Analysis
Current Asset Composition (May 2022)
Veritas Pharma Inc's total assets of $560.94K consist of 40.8% current assets and 59.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.7% |
| Accounts Receivable | $249.00 | 0.0% |
| Inventory | $241.86K | 31.8% |
| Property, Plant & Equipment | $450.09K | 59.2% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2022)
This chart illustrates how Veritas Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Veritas Pharma Inc's current assets represent 40.8% of total assets in 2022, a decrease from 100.0% in 2014.
- Cash Position: Cash and equivalents constituted 8.7% of total assets in 2022, down from 72.7% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is property, plant & equipment at 59.2% of total assets.
Veritas Pharma Inc Competitors by Total Assets
Key competitors of Veritas Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Veritas Pharma Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Veritas Pharma Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Veritas Pharma Inc is currently not profitable relative to its asset base.
Veritas Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.05 | 0.64 | 9.42 |
| Quick Ratio | 0.00 | 0.05 | 9.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-3.15 Million | $ -1.00 Million | $ 1.64 Million |
Veritas Pharma Inc - Advanced Valuation Insights
This section examines the relationship between Veritas Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.43 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | 104052.9% |
| Total Assets | $760.48K |
| Market Capitalization | $78.48K USD |
Valuation Analysis
Below Book Valuation: The market values Veritas Pharma Inc's assets below their book value (0.10 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Veritas Pharma Inc's assets grew by 104052.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Veritas Pharma Inc (2014–2022)
The table below shows the annual total assets of Veritas Pharma Inc from 2014 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-05-31 | $760.48K | +104052.93% |
| 2021-05-31 | $730.16 | -95.20% |
| 2020-05-31 | $15.22K | -97.30% |
| 2019-05-31 | $563.45K | -85.14% |
| 2018-05-31 | $3.79 Million | +36.73% |
| 2017-05-31 | $2.77 Million | +462.92% |
| 2016-05-31 | $492.59K | -1.65% |
| 2015-05-31 | $500.83K | +1200.15% |
| 2014-05-31 | $38.52K | -- |